Dr. Markus A. Lang is an accomplished biotech executive with over 20 years of leadership across drug development, company building, and strategic operations in the life sciences sector.

Adept at value creation in private & VC-backed biotechs by scaling organizations, transforming R&D-centric ventures into operationally robust, investor-ready businesses.

Extensive experience in bridging academic excellence with regulatory compliance and commercial scalability.

With profound expertise spanning the pharmaceutical value chain – from discovery to pivotal clinical development & registration – he made key contributions to groundbreaking therapies like Monjuvi®, Cyltezo®, Removab® and Pradaxa®.

• Founder & Strategic Advisor: Founder and Managing Director of Dr. Lang Consulting GmbH, where he has led high-impact advisory mandates for life science ventures. Spearheaded executive roles (interim CDO and COO) to reposition clinical-stage assets, drive post-merger integrations, and secure strategic partnerships and funding.
• Entrepreneurial CEO: Co-Founder & CEO of CD4 Therapeutics, steering the development of a first-in-class immunotherapy (Tregalizumab) to address critical unmet needs in T-cell mediated diseases. This venture underscores his entrepreneurial vision and commitment to transformative, patient-centric innovation in the biotech arena.
• Broad Pharma Expertise: Combines deep scientific acumen with strategic business insight to lead cross-functional teams through complex regulatory environments. Achieved key regulatory milestones (including FDA Breakthrough and Orphan Drug Designations) by aligning scientific innovation with clear regulatory and commercial strategies.
• Translating Vision into Action: Led transformation mandates including virtual-to-operational transitions, and scalable process implementation – with a passion for operational excellence and a track record of delivering results.